Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

NCT03051477 | Completed Phase 1 DMC FDA Drug

• 3 other identifiers: J1681IRB00090991Helixor
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

This study will seek to determine the safety and toxicity profile as well as the maximum tolerated dose of Helixor® M in patients with advanced solid tumors.

Conditions

Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Number of participants experiencing toxicities

  Number of participants who experience side effects

  3 years

• Maximum tolerated dose (MTD)

  The highest dose that does not cause unacceptable side effects

  2 years

Secondary Outcomes (1)

• Tumor marker kinetics

  3 years

Study Arms (1)

Helixor® M

EXPERIMENTAL

Advanced solid tumors

Drug: Helixor® M

Interventions

Helixor® M DRUG

3-hour IV infusion on Monday, Wednesday, and Friday of each week.

Also known as: Mistletoe extract

Helixor® M

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with advanced solid tumors and have received first line standard systemic therapy with chemotherapy, immunotherapy, hormonal therapy or other standard treatments for metastatic disease. Patients must either have progressed, are refractory, have stable disease and/or removed from therapy due to toxicities. Patients beyond first line therapy that do not meet criteria may be considered on a case by case basis and allowed at discretion of PI.
• Patients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessment. Prostate cancer patients with bone disease only are eligible.
• Age \>18 years.
• ECOG performance status 0-2
• Life expectancy of greater than 3 months.
• Patients must have normal organ and marrow function as defined below (without growth factor or transfusion support within 14 days prior to first dose of investigational product):
• WBC ≥ 3,000/mcL
• Absolute neutrophil count ≥ 1,000/mcL
• Platelets ≥ 90,000/mcL
• Hemoglobin ≥ 9.0 g/dL
• Total bilirubin ≤ 1.5 X ULN (patients with diagnosed Gilbert's Syndrome will not be excluded if their direct bilirubin is within normal institutional limits)
• AST(SGOT)/ALT(SGPT) ≤ 2.5 X ULN
• Creatinine ≤1.5 x ULN OR creatinine clearance ≥ 50 mL/min/1.73 m2
• Female patient of childbearing potential has a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.
• Female patients enrolled in the study, who are not free from menses for \>2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from heterosexual activity throughout the study, starting with Visit 1 through 28 days after the last dose of study therapy. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, female condoms with spermicide, or oral contraceptives. Spermicides alone are not an acceptable method of contraception.

You may not qualify if:

• Patient with a known history or evidence of brain metastases.
• Patients who have had chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior to the first dose of study drug excluding patients on long term hormonal therapies who have been on a stable dose for at least 3 months.
• Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drug.
• Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement.
• Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.
• Patient who has had prior treatment with Mistletoe.
• Patients who have received systemic corticosteroids within 28 days prior to the first dose of study drug. Note: Systemic steroid therapy is allowed for subjects on replacement therapy as long as prednisone ≤ 10 mg or its steroid equivalent.
• Patients who have received systemic NSAID therapy within 14 days prior to the first dose of study drug.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Mistletoe.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Presence of ≥ CTCAE grade 2 toxicity (except peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3) due to prior cancer therapy.
• Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis). History of Grave's disease on stable thyroid hormone replacement for at least 1 year is allowed.
• Patients with a known history of HIV, hepatitis B, hepatitis C, or tuberculosis infection. Patients with a history of cleared hepatitis C (undetectable viral loads) are allowed.
• Women with a positive pregnancy test on enrollment or prior to investigational product administration
• Women who are pregnant or breastfeeding.

Sponsors & Collaborators

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: lead
• Believe Big: collaborator

Study Sites (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States

Location

Study Officials

• Channing Paller, MD

  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2017
• First Posted: February 13, 2017
• Study Start: March 1, 2017
• Primary Completion: January 29, 2021
• Study Completion: August 5, 2022
• Last Updated: December 8, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)